Health

Companies engaged in biotechnology, pharmaceuticals, research services, home healthcare, hospital operations, long‑term care, and the manufacture and supply of medical equipment and supplies. The sector also includes pharmaceutical retailers and providers of health‑information services. UK‑listed companies in this sector include AstraZeneca plc, GlaxoSmithKline plc, Smith & Nephew plc, Hikma Pharmaceuticals plc, ConvaTec Group plc, Spire Healthcare plc and EMIS Group plc.

Gene therapy enters a more practical phase for biotech tnvestors

Gene therapy is moving closer to practical use, with Genflow’s delivery strategy and rare disease focus offering investors a clearer view of how scientific progress may translate into commercial opportunity...

April 24, 2026

Hikma reports solid start to 2026, maintains full-year outlook

Ahead of its Annual General Meeting, Hikma said all three businesses are performing well, announced a device partnership to support its generic Ellipta programme, and confirmed its 2026 revenue and..

April 23, 2026

Genflow Biosciences’ Dr Eric Leire highlights funding, pipeline progress and near-term catalysts

CEO Dr. Eric Leire discusses progress across Genflow’s dog study, glaucoma and sarcopenia programmes, recent grant funding, large market opportunities and upcoming milestones, including clinical results, partnering discussions and patent..

April 22, 2026

Verici Dx gains commercial momentum as Tutivia adoption builds

Commercial uptake of Verici Dx’s Tutivia test is accelerating, giving investors firmer evidence that adoption and reimbursement momentum may now be building together...

April 22, 2026

GenFlow Biosciences sharpens its longevity strategy

GenFlow Biosciences is making its longevity strategy more investable by backing the science with practical choices on manufacturing, platform design and regulatory progress...

April 20, 2026

Third positive Phase III trial supports AstraZeneca’s tozorakimab in COPD

High-level data from the MIRANDA study showed AstraZeneca’s IL-33-targeting biologic tozorakimab significantly lowered annualised moderate-to-severe COPD exacerbations and was generally well tolerated...

April 20, 2026

GSK wins China approval for Blenrep in previously treated multiple myeloma

The approval covers Blenrep plus bortezomib and dexamethasone for adults with relapsed or refractory multiple myeloma and is supported by phase III DREAMM-7 data showing progression-free and overall survival benefits...

April 20, 2026

Genflow Biosciences partners with Acuitas to advance SIRT6 mRNA programme

Genflow Biosciences has entered a fully funded collaboration with Acuitas Therapeutics to apply lipid nanoparticle delivery technology to its SIRT6 mRNA platform, supporting preclinical development for age-related diseases...

April 20, 2026

Physicians Capital: Why Dr. Conrad Ivie Believes Doctors Must Reclaim Ownership Before Burnout Wins (video)

April 17, 2026

Brava Health uses AI to transform patient data into real-time clinical insight, says Dr Michael Karch

Dr Michael Karch of Brava Health argues that clinician resistance to AI is often misread. The real issue is not opposition to technology, but concern about how it is framed..

April 16, 2026

Verici Dx sees accelerating Tutivia adoption in Q1 2026 trading update

In its Q1 2026 trading update, Verici Dx reported a 34% year-on-year increase in Tutivia testing volumes, growing use across US transplant centres and continued confidence in commercial traction through..

April 16, 2026

GSK adds pulmonary hypertension candidate HS235 through 35Pharma acquisition

GSK has closed its acquisition of 35Pharma, gaining HS235, a potential treatment for pulmonary hypertension that targets the activin receptor signalling pathway and is expected to enter proof-of-concept trials soon...

April 15, 2026

Operating room efficiency is emerging as a real investment issue

Healthcare providers are starting to treat operating room efficiency as a way to create capacity and improve performance, not just divide limited theatre time...

April 13, 2026

Oxford Biomedica launches fast-track viral vector manufacturing service

Oxford Biomedica has introduced a fast-track development and manufacturing offering for AAV and lentiviral vectors, aiming to shorten the route to GMP manufacture and help biotech clients reach clinical milestones..

April 13, 2026

Genflow Biosciences eyes pivotal catalysts across MASH, glaucoma and animal health (video)

April 13, 2026

Halma acquires ophthalmic instruments maker Surgistar for $90m

Halma has acquired California-based Surgistar, a manufacturer of ophthalmic surgical instruments and devices, for $90 million as a bolt-on to MicroSurgical Technology, strengthening its ophthalmic product offering and manufacturing capabilities...

April 13, 2026

EDX Medical seeks AIM admission as it prepares to leave Aquis

EDX Medical has announced plans to transfer its ordinary shares from the Aquis Stock Exchange to AIM, with admission and withdrawal expected to take effect simultaneously on 13 May 2026...

April 13, 2026

Genflow Biosciences expands SIRT6 patent coverage into frailty and sarcopenia

Genflow Biosciences has announced the publication of an international patent application related to SIRT6 variants for muscular diseases, extending its intellectual property strategy beyond longevity and metabolic indications...

April 13, 2026

Vereci Dx highlights ongoing need for kidney disease awareness

Vereci Dx says kidney disease awareness should continue beyond National Kidney Month because many adults remain affected without knowing it...

April 9, 2026

Convatec sets out ‘Accelerate’ strategy to drive faster sustainable growth

Convatec has introduced its new Accelerate strategy, outlining four strategic pillars and reaffirming medium-term guidance including 6–8% annual organic revenue growth, a 24–26% adjusted operating margin and double-digit growth in..

April 9, 2026

News and Interview Alerts

Company Presentations

Ilika plc: A New Era in Solid-State Battery Innovation – 2024 Investor Presentation

Time Finance PLC Strong Growth and Strategic Progress: A Message from CEO Ed Rimmer

SAE Renewables Future Strategy to 2035 and Investment Case by Graham Reid CEO

One Health Group (AQSE:OHGR) final results presentation

Q&As

Mark Clubb outlines TEAM plc’s FY25 progress and acquisition strategy

7 April 2026

Criterium Energy’s CEO Matthew Klukas on the Indonesia growth strategy (TSX:CEQ)

7 April 2026

Hardman & Co

ICG Enterprise Trust FY’26 results: look to future realisations

11 June 2026

NB Private Equity Partners 2025 results: Looking to future realisations

29 May 2026

Chesnara Plc: Showing good operational progress

17 April 2026

Arbuthnot Banking Group Plc: 2025 lower margins, 2026 profit stability

1 April 2026

Green News

Quadrise reports progress on Valkor pilot deployment in Utah

12 June 2026

Thor Energy reports elevated hydrogen results at HY-Range project

9 June 2026

Drax agrees £548m cash acquisition of Bluefield Solar Income Fund

1 June 2026

Drax completes commissioning of Hirwaun Power Station

29 May 2026

View all Sustainable sectors, Plcs and news >>

Search

Latest Interviews

BrokerTalk

Chariot Positioned for Growth as Cavendish Highlights Angola and Renewables Opportunity

11 May 2026

Diversified Energy Q1 Results Impress as Carlyle Partnership Opens New Growth Chapter, Tennyson Securities

8 May 2026

IP Group’s New Chair Designate Signals Confidence in Long Term Growth, Equity Development

7 May 2026

Drax Group Trading Update Highlights Strong Visibility and Strategic Flexibility, Says Longspur Research

7 May 2026

Ferro-Alloy Resources Progresses Balasausqandiq Development as Panmure Liberum Maintains BUY Rating

7 May 2026

Funds

Diverse Income Trust: UK equity outlook and reconstruction proposal (LON:DIVI)

11 June 2026

Biotech Growth Trust reports strong one-year performance

11 June 2026

Ruffer Investment Company delivers positive year-to-date gains

11 June 2026

Finsbury Growth & Income Trust highlights portfolio value in May

9 June 2026

GSK to acquire Biotech Growth Trust portfolio company Nuvalent for $10.6bn

9 June 2026

View all Funds, Market Insights and news >>

FTSE 100 News

FTSE 100 slips as blue-chip caution weighs on London market

9 June 2026

GSK to acquire Biotech Growth Trust portfolio company Nuvalent for $10.6bn

9 June 2026

Smiths Group appoints Laurence Mulliez as Independent Non-executive Director

8 June 2026

Howdens to acquire DIY Kitchens for £390m

3 June 2026

UK Broker Ratings

Goodwin PLC (GDWN.L) Stock Analysis: A Hidden Gem in Specialty Industrial Machinery with Robust Revenue Growth

9 June 2026

FirstGroup PLC (FGP.L) Stock Analysis: Examining a Potential 50% Upside for Investors

9 June 2026

Chemring Group PLC (CHG.L) Stock Analysis: Aerospace & Defense Player with a 22% Upside Potential

9 June 2026

Hilton Food Group PLC (HFG.L) Stock Analysis: Uncovering a 34.97% Potential Upside in the Packaged Foods Sector

9 June 2026

ABERDEEN GROUP PLC (ABDN.L) Stock Analysis: Navigating the Investment Landscape with a 6.12% Dividend Yield

9 June 2026

Health

Gene therapy enters a more practical phase for biotech tnvestors

April 24, 2026

Hikma reports solid start to 2026, maintains full-year outlook

Ahead of its Annual General Meeting, Hikma said all three businesses are performing well, announced a device partnership to support its generic Ellipta programme, and confirmed its 2026 revenue and profit guidance remains unchanged...

April 23, 2026

Genflow Biosciences’ Dr Eric Leire highlights funding, pipeline progress and near-term catalysts

April 22, 2026

Verici Dx gains commercial momentum as Tutivia adoption builds

Commercial uptake of Verici Dx’s Tutivia test is accelerating, giving investors firmer evidence that adoption and reimbursement momentum may now be building together...

April 22, 2026

GenFlow Biosciences sharpens its longevity strategy

GenFlow Biosciences is making its longevity strategy more investable by backing the science with practical choices on manufacturing, platform design and regulatory progress...

April 20, 2026

Third positive Phase III trial supports AstraZeneca’s tozorakimab in COPD

April 20, 2026

GSK wins China approval for Blenrep in previously treated multiple myeloma

April 20, 2026

Genflow Biosciences partners with Acuitas to advance SIRT6 mRNA programme

April 20, 2026

Physicians Capital: Why Dr. Conrad Ivie Believes Doctors Must Reclaim Ownership Before Burnout Wins (video)

Dr. Conrad Ivie breaks down why more physicians are burning out while owning less of the healthcare system they power. From building Tennessee’s largest orthopaedic group to launching Physicians Capital, he explains why real estate, financial fluency and long-term ownership are becoming essential for doctors who want more than income tied to time...

April 17, 2026

Brava Health uses AI to transform patient data into real-time clinical insight, says Dr Michael Karch

Dr Michael Karch of Brava Health argues that clinician resistance to AI is often misread. The real issue is not opposition to technology, but concern about how it is framed and applied in practice, with the strongest opportunities lying in tools that support judgment rather than replace it...

April 16, 2026

Verici Dx sees accelerating Tutivia adoption in Q1 2026 trading update

April 16, 2026

GSK adds pulmonary hypertension candidate HS235 through 35Pharma acquisition

April 15, 2026

Operating room efficiency is emerging as a real investment issue

Healthcare providers are starting to treat operating room efficiency as a way to create capacity and improve performance, not just divide limited theatre time...

April 13, 2026

Oxford Biomedica launches fast-track viral vector manufacturing service

April 13, 2026

Genflow Biosciences eyes pivotal catalysts across MASH, glaucoma and animal health (video)

Genflow Biosciences is approaching a run of meaningful catalysts, with Dr Eric Leire highlighting promising interim dog study data, a differentiated glaucoma programme and fresh non-dilutive funding. He also explains why the company sees major commercial potential across late-stage MASH, glaucoma and sarcopenia, and what investors should watch next on partnerships, data and IP...

April 13, 2026

Halma acquires ophthalmic instruments maker Surgistar for $90m

April 13, 2026

EDX Medical seeks AIM admission as it prepares to leave Aquis

EDX Medical has announced plans to transfer its ordinary shares from the Aquis Stock Exchange to AIM, with admission and withdrawal expected to take effect simultaneously on 13 May 2026. The company says the move is intended to improve access to growth capital, investor visibility and share liquidity...